Zoetis
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 14.1K
- Market Cap
- $82.5B
- Introduction
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.
FDA Issues Warning for Zoetis' Canine Osteoarthritis Drug Librela After Reports of Serious Adverse Reactions
The FDA has issued a warning about Zoetis' canine osteoarthritis drug Librela following 3,674 reports of adverse reactions, including 458 deaths as of April 2024.
Syngene International Expands Global Footprint with $50 Million US Biologics Facility Acquisition
Syngene International has acquired its first US biologics manufacturing facility near Baltimore for $36.5 million, with plans to invest an additional $13.5 million in upgrades to make it operational by mid-2025.
USDA Grants Conditional Approval for Zoetis' Avian Influenza Vaccine
The USDA has granted conditional approval to Zoetis for a new bird flu vaccine, marking a significant advancement in poultry disease prevention.
FDA Halts Moderna's Norovirus Vaccine Trial Following Guillain-Barré Case
The U.S. FDA has placed a clinical hold on Moderna's late-stage norovirus vaccine trial (mRNA-1403) after a reported case of Guillain-Barré syndrome.
Zoetis Updates Librela Label Following Reports of Severe Side Effects in Dogs
Zoetis has revised the prescribing information for its canine arthritis drug Librela to include warnings about rare but serious adverse effects reported since its U.S. launch in 2023.
AVMA and Cornell University Launch Clinical Trial to Combat Veterinary Burnout
The AVMA and Cornell University are collaborating on a clinical trial to address burnout among veterinary professionals, funded by AVMA and Zoetis.
FDA Approves First Generic Propofol Injectable Emulsion for Dogs
The FDA has approved the first generic propofol injectable emulsion, PropofolVet Multidose, for use as an anesthetic in dogs.
Elanco's Zenrelia (Ilunocitinib) Receives FDA Approval for Canine Dermatitis
Elanco's Zenrelia (ilunocitinib) has gained FDA approval as a once-daily oral treatment for pruritus associated with allergic dermatitis and atopic dermatitis in dogs.